Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.

ABSTRACT:

Objective

To compare extra-lipid effects of statins and fibrates in relation to the baseline metabolic status of patients.

Research design and methods

The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo.

Results

Compared with matched healthy subjects, metabolic syndrome patients exhibited higher plasma levels/activities of high-sensitivity C-reactive protein (hs-CRP), fibrinogen, factor VII, plasminogen activator inhibitor 1, and enhanced monocyte cytokine release. These abnormalities were alleviated by both atorvastatin and fenofibrate treatment. CRP-lowering and monocyte-suppressing actions were more pronounced for atorvastatin in subjects with impaired fasting glucose and

SUBMITTER: Krysiak R 

PROVIDER: S-EPMC2945172 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature